Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Calcitriol in the treatment of prostate cancer.

Beer TM, Myrthue A.

Anticancer Res. 2006 Jul-Aug;26(4A):2647-51. Review.

2.

Calcitriol in cancer treatment: from the lab to the clinic.

Beer TM, Myrthue A.

Mol Cancer Ther. 2004 Mar;3(3):373-81. Review.

3.

Development of weekly high-dose calcitriol based therapy for prostate cancer.

Beer TM.

Urol Oncol. 2003 Sep-Oct;21(5):399-405. Review.

PMID:
14670552
4.

Vitamin D receptor: a potential target for intervention.

Johnson CS, Hershberger PA, Bernardi RJ, Mcguire TF, Trump DL.

Urology. 2002 Sep;60(3 Suppl 1):123-30; discussion 130-1. Review.

PMID:
12231068
5.

Rationale for combination ketoconazole/ vitamin D treatment of prostate cancer.

Peehl DM, Seto E, Feldman D.

Urology. 2001 Aug;58(2 Suppl 1):123-6. Review.

PMID:
11502466
6.

Satraplatin: BMS 182751, BMY 45594, JM 216.

[No authors listed]

Drugs R D. 2007;8(2):125-32. Review.

PMID:
17324011
7.

Rationale for the development and current status of calcitriol in androgen-independent prostate cancer.

Beer TM, Myrthue A, Eilers KM.

World J Urol. 2005 Feb;23(1):28-32. Epub 2005 Jan 25. Review.

PMID:
15668801
8.

Anti-tumor activity of calcitriol: pre-clinical and clinical studies.

Trump DL, Hershberger PA, Bernardi RJ, Ahmed S, Muindi J, Fakih M, Yu WD, Johnson CS.

J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):519-26. Review.

PMID:
15225831
10.

Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.

Medina PJ, Goodin S.

Clin Ther. 2008 Aug;30(8):1426-47. doi: 10.1016/j.clinthera.2008.08.008. Review.

PMID:
18803986
11.

Therapies in development for castrate-resistant prostate cancer.

Harzstark AL, Ryan CJ.

Expert Rev Anticancer Ther. 2008 Feb;8(2):259-68. doi: 10.1586/14737140.8.2.259. Review.

PMID:
18279066
12.

Vitamin D and prostate cancer.

Konety BR, Getzenberg RH.

Urol Clin North Am. 2002 Feb;29(1):95-106, ix. Review.

PMID:
12109360
13.

Intermittent chemotherapy for metastatic hormone refractory prostate cancer.

Lin AM, Ryan CJ, Small EJ.

Crit Rev Oncol Hematol. 2007 Mar;61(3):243-54. Epub 2006 Dec 11. Review.

PMID:
17161610
14.

The development of vitamin D-based therapies for prostate cancer.

Price N.

Clin Prostate Cancer. 2004 Mar;2(4):202-5. Review. No abstract available.

PMID:
15072600
15.
16.

Molecular basis of the potential of vitamin D to prevent cancer.

Ingraham BA, Bragdon B, Nohe A.

Curr Med Res Opin. 2008 Jan;24(1):139-49. Review.

PMID:
18034918
17.

Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy.

Trump DL, Deeb KK, Johnson CS.

Cancer J. 2010 Jan-Feb;16(1):1-9. doi: 10.1097/PPO.0b013e3181c51ee6. Review.

18.

Novel cytotoxic and biological agents for prostate cancer: where will the money be in 2005?

Strother JM, Beer TM, Dreicer R.

Eur J Cancer. 2005 Apr;41(6):954-64. Review.

PMID:
15808961
19.

The mechanism of calcitriol in cancer prevention and treatment.

Ma J, Ma Z, Li W, Ma Q, Guo J, Hu A, Li R, Wang F, Han S.

Curr Med Chem. 2013;20(33):4121-30. Review.

PMID:
23895685
20.

Calcitriol in Combination Therapy for Prostate Cancer: Pharmacokinetic and Pharmacodynamic Interactions.

Ben-Eltriki M, Deb S, Guns ES.

J Cancer. 2016 Jan 15;7(4):391-407. doi: 10.7150/jca.13470. eCollection 2016. Review.

Supplemental Content

Support Center